Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Market Cap Dropped CN¥417m Last Week; Individual Investors Who Hold 31% Were Hit as Were Institutions
Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Market Cap Dropped CN¥417m Last Week; Individual Investors Who Hold 31% Were Hit as Were Institutions
Key Insights
主要見解
- Significant control over Jianzhijia Pharmaceutical Chain Group by retail investors implies that the general public has more power to influence management and governance-related decisions
- The top 5 shareholders own 51% of the company
- Insider ownership in Jianzhijia Pharmaceutical Chain Group is 27%
- 零售投資者對建之佳連鎖藥店集團的重大控制意味着普通公衆有更多的權力來影響管理和治理相關決策。
- 該公司的前五大股東擁有51%的股份。
- 建之佳連鎖藥店集團的內部持股比例爲27%。
To get a sense of who is truly in control of Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 31% to be precise, is retail investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
爲了了解真正控制建之佳集團的是誰,了解企業的所有權結構非常重要。在該公司持有最多股份的集團中,約佔31%的是零售投資者。換句話說,該集團將從其對公司的投資中獲得最大收益(或虧損最大)。
While the holdings of retail investors took a hit after last week's 11% price drop, institutions with their 27% holdings also suffered.
雖然上週價格暴跌11%對零售投資者的持股產生了影響,但持有27%股份的機構也遭受了損失。
In the chart below, we zoom in on the different ownership groups of Jianzhijia Pharmaceutical Chain Group.
在下面的圖表中,我們將重點關注建之佳連鎖藥店集團的不同所有權群體。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-88fbcb363320e365643fa585f8aa2e8f-0-a76ae4e4782447832a542df328ab93b8.png/big)
What Does The Institutional Ownership Tell Us About Jianzhijia Pharmaceutical Chain Group?
機構投資者持有建之佳連鎖藥店集團的股份告訴我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。
As you can see, institutional investors have a fair amount of stake in Jianzhijia Pharmaceutical Chain Group. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Jianzhijia Pharmaceutical Chain Group's historic earnings and revenue below, but keep in mind there's always more to the story.
正如您所看到的,機構投資者在建之佳連鎖藥店集團中持有相當比例的股份。這可能表明該公司在投資界具有一定的信譽度。然而,最好謹慎依靠機構投資者所謂的認可。他們也有時候錯了。當多個機構擁有一支股票時,總有一種“擁擠的交易”的風險。當這樣的交易出現問題時,多個交易方可能會競相快速賣出股票。在沒有增長曆史的公司中,這種風險更大。您可以在下面看到建之佳連鎖藥店集團的歷史收入和營業收入,但請記住,故事總有更多的內容。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-88fbcb363320e365643fa585f8aa2e8f-1-13f5403048e1709c06ff4cd93db67685.png/big)
We note that hedge funds don't have a meaningful investment in Jianzhijia Pharmaceutical Chain Group. Looking at our data, we can see that the largest shareholder is the CEO Bo Lan with 17% of shares outstanding. In comparison, the second and third largest shareholders hold about 15% and 9.9% of the stock.
我們注意到,對建之佳連鎖藥店集團的投資並不意味着對沖基金有重要的投資。通過查看我們的數據,我們可以看到最大的股東是持有17%流通股的CEO Bo Lan。與之相比,第二大和第三大股東持有的股份約爲15%和9.9%。
Our research also brought to light the fact that roughly 51% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.
我們的研究還發現,約51%的公司股份由前5大股東控制,表明這些所有者對公司業務具有重要影響力。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
研究機構所有權是衡量和過濾股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。雖然該公司有一些分析師關注,但它可能沒有得到廣泛關注。因此,它可能在未來得到更多關注。
Insider Ownership Of Jianzhijia Pharmaceutical Chain Group
建之佳連鎖藥店集團內部持股情況
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。
It seems insiders own a significant proportion of Jianzhijia Pharmaceutical Chain Group Co., Ltd.. Insiders own CN¥874m worth of shares in the CN¥3.3b company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
看起來內部人士擁有建之佳連鎖藥店集團的相當大比例。內部人士擁有該33億元公司中的87400萬元人民幣的股份。看到內部人士對業務的如此投入非常好。檢查一下這些內部人員最近是否一直在購買股票可能是值得的。
General Public Ownership
一般大衆所有權
With a 31% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Jianzhijia Pharmaceutical Chain Group. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
擁有31%的所有權的普通公衆,主要包括個人投資者,在建之佳連鎖藥店集團中具有一定的影響力。雖然這個群體不能直接決策,但肯定對公司的運營產生了真正的影響。
Private Company Ownership
私有公司的所有權
We can see that Private Companies own 15%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我們可以看到,非上市公司擁有已發行股份的15%。也許有必要深入研究一下。如果相關方,如內部人員,在這些私人公司中擁有利益,那麼應該在年報中發表說明。非上市公司也可能對該公司有戰略利益。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for Jianzhijia Pharmaceutical Chain Group you should be aware of.
雖然考慮擁有公司的不同群體值得參考,但仍有其他更重要的因素。一個例子:我們發現建之佳連鎖藥店集團存在2個警告信號,您應該注意。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。